Learning Outcome
Participants will be able to identify at least three evidence-based strategies that are designed to enhance the clinical team-based care of patients with substance or opioid use disorders treatment.
Presenter
Hendreé Jones, PhD
About our Presenter
Hendreé Jones, PhD, ia a professor in the Department of Obstetrics and Gynecology at the School of Medicine, University of North Carolina in Chapel Hill. She is also the executive director of UNC Horizons, a comprehensive drug treatment program for pregnant and parenting women and their drug-exposed children. She is also an Adjunct Professor in the Department of Psychology at UNC-Chapel Hill and an Adjunct Professor in the Psychiatry and Behavioral Sciences and in the Department of Obstetrics and Gynecology, School of Medicine at Johns Hopkins University. Dr. Jones is an internationally recognized expert in the development and examination of both behavioral and pharmacologic treatments for pregnant women and their children in risky life situations. She has received continuous National Institutes of Health funding since 1994 and has written more than 195 peer-reviewed publications. Dr. Jones has also authored two books, one on treating patients for substance use disorders and the other on comprehensive care for women who are pregnant and have substance use disorders. She also has written multiple textbook chapters on the topic of pregnancy and addiction, as well as editorial letters and non-peer-reviewed articles for clinicians.
Disclosure
The activity director(s), planning committee member(s), speaker(s), author(s) or anyone in a position to control the content for this activity have reported NO financial relationship(s)* with ineligible companies**.
* A “financial relationship" includes employee, researcher (named as the PI), consultant, advisor, speaker, independent contractor (including contracted research), royalties or patent beneficiary, executive role, and/or an ownership interest (not including stocks owned in a managed portfolio).
** An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Bibliographic Material
O’Neill K. How Far Along? How Vermont Delivers Help for Pregnant Women With Opioid-Use Disorder Seven Days. August 21, 2019.
Rutman D, Hubberstey, C., Van Bibber M., Poole, N., Schmidt, R.,. Co-Creating Evidence Project. National Evaluation of Multi-service Programs Reaching Pregnant Women at Risk 2019; http://www.fasd-evaluation.ca/wp-content/uploads/2020/08/CCE-programs-wrap-around-services-standalone-graphic-December-2019.pdf.
Goodman D, Zagaria AB, Flanagan V, et al. Feasibility and Acceptability of a Checklist and Learning Collaborative to Promote Quality and Safety in the Perinatal Care of Women with Opioid Use Disorders. Journal of Midwifery & Women's Health. 2019;64(1):104-111.
Connock M, Juarez-Garcia A, Jowett S, et al. Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. Health Technol Assess. 2007;11(9):1-171, iii-iv.
Substance Abuse and Mental Health Services Administration. Clinical Guidance for Treating Pregnant and Parenting Women with Opioid Use Disorder and Their Infants. https://store.samhsa.gov/sites/default/files/d7/priv/sma18-5054.pdf. Accessed May 29, 2021.
Rizk AH, Simonsen SE, Roberts L, Taylor-Swanson L, Lemoine JB, Smid M. Maternity Care for Pregnant Women with Opioid Use Disorder: A Review. Journal of Midwifery & Women's Health. 2019;64(5):532-544.
Higgins ST. Behavior change, health, and health disparities 2019: Opioids, tobacco, and treatment adherence. Prev Med. 2019;128:105887.
British Columbia Centre on Substance Use. A Guideline for the Clinical Management of Opioid Use Disorder Pregnancy Supplement. 2018; https://www.bccsu.ca/wp-content/uploads/2018/06/OUD-Pregnancy.pdf. Accessed May 29, 2021.
British Columbia Centre on Substance Use. A Guideline for the Clinical Management of Opioid Use Disorder Pregnancy Supplement. 2018; https://www.bccsu.ca/wp-content/uploads/2018/06/OUD-Pregnancy.pdf. Accessed May 29, 2021.
Constance Guille, M.D. , M.S.C.R. ,, Hendree E. Jones, Ph.D. ,, Alfred Abuhamad, M.D. ,, Kathleen T. Brady, M.D. , Ph.D. Shared Decision-Making Tool for Treatment of Perinatal Opioid Use Disorder. Psychiatric Research and Clinical Practice. 2019;1(1):27-31.
Ramage M, Tak C, Goodman D, Johnson E, Barber C, Jones HE. Improving access to care through Advanced Practice Registered Nurses: Focus on perinatal patients with Opioid Use Disorder. Journal of Advanced Nursing. 2021;77(1):4-10.
McRae DN, Muhajarine N, Janssen PA. Improving birth outcomes for women who are substance using or have mental illness: a Canadian cohort study comparing antenatal midwifery and physician models of care for women of low socioeconomic position. BMC Pregnancy and Childbirth. 2019;19(1):279.
Schiff DM, Nielsen T, Terplan M, et al. Fatal and Nonfatal Overdose Among Pregnant and Postpartum Women in Massachusetts. Obstet Gynecol. 2018;132(2):466-474.
Whiteman VE, Salemi JL, Mogos MF, Cain MA, Aliyu MH, Salihu HM. Maternal opioid drug use during pregnancy and its impact on perinatal morbidity, mortality, and the costs of medical care in the United States. J Pregnancy. 2014;2014:906723.
National Infants Assistance Resource Center. Research to Practice Brief: Supporting Children of Parents with Co-occurring Mental Illness and Substance Abuse. 2012; http://www.ncdsv.org/images/NAIARC_SupportingChildrenOfParentsCo-OccurringMHandSubstanceAbuse_6-2012.pdf. Accessed May 29, 2021.
